Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL122808 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1396195 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL735586 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1076271 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL156385 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL734680 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL232957 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL736397 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2020039 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL14760076 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178108-B2 | Methods for expression and purification of recombinant human growth hormone | AMBRX, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178494-B2 | hGH polypeptide comprises one or more post-translational modifications; is linked to a linker, polymer, or biologically active molecule; linked to a bifunctional polymer, bifunctional linker, or at least one additional hGH polypeptide | AMBRX, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163695-B2 | hGH polypeptide comprises one or more post-translational modifications; is linked to a linker, polymer, or biologically active molecule; linked to a bifunctional polymer, bifunctional linker, or at least one additional hGH polypeptide | AMBRX (US) | 2012-04-24 | — | — | US | disclosed |
| US-8080391-B2 | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer | AMBRX, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110195899-A1 | Formulations of Human Growth Hormone Comprising a Non-Naturally Encoded Amino Acid | AMBRX, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7959926-B2 | Using hydrophobic interaction chromatography (HIC) matrix to recover somatotropins | AMBRX, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7947473-B2 | Propagating somatotropin in transgenic escherichia; recovering hormone via hydrophobic interaction chromatography | AMBRX, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7816320-B2 | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 | AMBRX, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1836316-A4 | METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE | AMBRX INC (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1833993-A4 | FORMULATIONS OF HUMAN GROWTH HORMONE COMPRISING A NON-NATURALLY ENCODED AMINO ACID | AMBRX INC (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1836316-A2 | METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE | Ambrx, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1833993-A2 | FORMULATIONS OF HUMAN GROWTH HORMONE COMPRISING A NON-NATURALLY ENCODED AMINO ACID | Ambrx, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060183198-A1 | Methods for expression and purification of recombinant human growth hormone | AMBRX, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006073846-A2 | METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006071840-A2 | FORMULATIONS OF HUMAN GROWTH HORMONE COMPRISING A NON-NATURALLY ENCODED AMINO ACID | AMBRX, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060135427-A1 | Formulations of human growth hormone comprising a non-naturally encoded amino acid | AMBRX, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2004043356-A2 | COATED DIBASIC CALCIUM PHOSPHATE | METRICS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040091544-A1 | Applying a solution of the active pharmaceutical ingredient, e.g. a peptide such as insulin, to form a coating on a particulate substrate which is free of a polysaccharide; permeation promoter coating to control release; capsules | METRICS, INC. | 2004-05-13 | — | — | US | disclosed |
| CN-1371284-A | Multi-dose erythropoietin formulations | AVENTIS PHARMA INC (US) | 2002-09-25 | — | — | CN | disclosed |
| WO-1995012686-A1 | METHOD FOR SCREENING FOR COMPOUNDS WHICH CHANGE THE TYROSINE HYDROXYLASE CONTENT OF INTACT CELLS IN CULTURE | CEPHALON, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183198-A1 | Methods for expression and purification of recombinant human growth hormone | GHITM, GHRHR, GHSR | LMNA 4784/4885SLC34A1 2628/4885KDM4E 4144/4885 |
| US-20060135427-A1 | Formulations of human growth hormone comprising a non-naturally encoded amino acid | GHRHR, GHITM, GHSR | LMNA 4104/4885SLC34A1 823/4885KDM4E 3663/4885 |
| US-20110195899-A1 | Formulations of Human Growth Hormone Comprising a Non-Naturally Encoded Amino Acid | GHRHR, GHITM, GHSR | LMNA 4104/4885SLC34A1 823/4885KDM4E 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.